In the current study, we demonstrated for the first time that specific blockade of GH/GHR signaling pathway using pegvisomant, an FDA-approved drug, potentiates the effects of sorafenib and overcomes its resistance in nude mice xenograft tumors as well as in two HCC patients who developed resistance and progressed on sorafenib. This evidence concerns the gene GHR and hepatocellular carcinoma.